GLP-1 Agonist Crystal Forms for Stability and Oral Drug Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GLP-1 receptor agonists, such as peptidic compounds like liraglutide and exenatide, have poor oral bioavailability and inconvenient administration, while crystalline forms of these compounds can affect chemical stability and require improved storage and production conditions.
Innovation Solution
Development of crystalline forms A through G of the compound 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, each with distinct X-ray powder diffraction patterns, and methods for their preparation using various solvents and crystallization techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptidic GLP-1 receptor agonists are used to improve blood glucose control, then therapeutic effect is improved, but oral bioavailability deteriorates
Solution Approach 1:
The patent changes the chemical structure parameters from peptidic to non-peptidic small molecule compounds, fundamentally altering the molecular properties to achieve both good oral bioavailability and therapeutic effect on GLP-1 receptors
Solution Approach 2:
The patent replaces the peptidic chemical structure with a small molecule structure featuring specific functional groups (benzimidazole, piperidine, dioxane rings), substituting one chemical system with another that overcomes the bioavailability limitation while maintaining receptor activity
2Productivity
If amorphous drug product is used, then dissolution is improved, but product stability deteriorates
Solution Approach 1:
The patent utilizes crystallization phase transitions to convert the amorphous drug substance into defined crystal forms, achieving a balance between dissolution properties and long-term stability through controlled phase change from amorphous to crystalline state
Solution Approach 2:
The patent changes the physical state parameters of the drug substance from amorphous to crystalline forms with specific X-ray diffraction patterns, altering the molecular arrangement to simultaneously achieve acceptable dissolution and improved stability
3Adaptability or versatility
If different crystallization conditions are applied, then crystal structure varies, but product consistency deteriorates
Solution Approach 1:
The patent identifies and characterizes specific local crystal structures (Crystal Form A, B, C, D, E, F, G) with distinct X-ray diffraction patterns, allowing selective production of specific crystal forms with predetermined properties through controlled crystallization conditions
Solution Approach 2:
The patent employs controlled phase transitions during crystallization using specific solvents and temperature profiles to reproducibly generate consistent crystal forms, ensuring product consistency while maintaining the ability to produce different crystal polymorphs as needed
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms enhance chemical stability, improve production processes, and provide a basis for pharmaceutical compositions with potential therapeutic applications targeting GLP-1 receptors.
Implementation Method 1
Development of crystalline forms A through G of the compound 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, each with distinct X-ray powder diffraction patterns, and methods for their preparation using various solvents and crystallization techniques
Implementation Method 2
an X-ray powder diffraction pattern expressed with diffraction angle 2θ has no obvious characteristic peaks
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A crystalline form of a GLP-1 receptor agonist and a preparation method therefor. The agonist is a compound 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b] [1,4] dioxane-5 -yl)piperidin- 1 -yl)methyl)-1 -(((S)-oxe-tan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid.